Form 4: Cadrenal CEO Sells Shares Under 10b5-1 Plan

Cadrenal Therapeutics CEO and Chairman Quang X. Pham sold 3,600 shares of common stock in two transactions under a Rule 10b5-1 trading arrangement.

Summary

• Quang X. Pham, the CEO and Chairman of Cadrenal Therapeutics, Inc. (CVKD), reported the sale of common stock.
• On October 9, 2025, 1,800 shares were sold at a weighted average price of $14.02 per share, with prices ranging from $13.99 to $14.11.
• On October 13, 2025, an additional 1,800 shares were sold at a weighted average price of $14.15 per share, with prices ranging from $13.99 to $14.33.
• These transactions were executed in accordance with a pre-arranged Rule 10b5-1 trading arrangement.
• Following these sales, Mr. Pham directly beneficially owns 198,533 shares of common stock.
• Mr. Pham also indirectly beneficially owns 200,000 shares through The PVBQ Living Trust, where he serves as the Trustee and his child is the sole beneficiary.

Sentiment

Score: 4

Explanation: The sale of shares by the CEO and Chairman, even if pre-planned, generally carries a negative sentiment as it reduces insider ownership and can be perceived as a lack of confidence or a belief that the stock is fully valued. The 10b5-1 plan mitigates some of the immediate negative implications but does not eliminate the signal entirely.

Negatives

• Insider selling by the CEO and Chairman, even under a pre-arranged plan, can be perceived negatively by the market, potentially signaling a belief that the stock is fully valued or a lack of confidence in near-term prospects.
• A reduction in the direct beneficial ownership of a key executive.

Future Outlook

NA

Industry Context

This filing is a standard insider transaction report and does not provide specific industry context. However, insider selling, even under a 10b5-1 plan, is often scrutinized by the market for potential signals regarding management's perception of the company's valuation or future prospects within its industry.

Related Party Transactions

• Quang Pham is the Trustee of The PVBQ Living Trust, which holds 200,000 shares, and his child is the sole beneficiary. This represents an indirect beneficial ownership by a related party.

Stakeholder Impact

• Shareholders may interpret the insider selling as a signal regarding the company's valuation or future performance, potentially influencing their investment decisions.

Key Dates

Recommendation

While insider selling by the CEO and Chairman is generally a negative signal, the transactions were conducted under a Rule 10b5-1 trading arrangement, which suggests a pre-planned sale rather than an immediate reaction to new information. This mitigates some of the negative implications. Investors should monitor future filings and company performance, but a 'hold' recommendation is appropriate given the pre-planned nature of the sales and the executive's continued significant direct and indirect ownership.

Keywords

Cadrenal Therapeutics, CVKD, Quang X. Pham, Insider Selling, Form 4, SEC Filing, Stock Sale, 10b5-1 Plan, CEO, Chairman